Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Epilepsy Behav. 2020 Nov;112:107343. doi: 10.1016/j.yebeh.2020.107343. Epub 2020 Aug 2.
N-methyl-d-aspartate receptor (NMDA-R)/nitric oxide (NO) pathway is involved in the intensification of the analgesic effect of opioids and the reduction of the intensity of opioids tolerance and dependence. In the current study, we investigated the involvement of NMDA-R/NO pathway in chronic morphine-treated mice in both the development of tolerance to the analgesic effect of morphine and in pentylenetetrazole (PTZ)-induced seizure threshold. Chronic treatment with morphine (30 mg/kg) exhibited increased seizure resistance in morphine-induced tolerant mice. The development of morphine tolerance was withdrawn when used concomitantly with NOS inhibitors and NMDA-R antagonist, suggesting that the development of tolerance to the anticonvulsant effect of morphine (30 mg/kg) is mediated through the NMDA-R/NO pathway. A dose-dependent biphasic seizure modulation of morphine was demonstrated in the acute treatment with morphine; acute treatment at a dose of 0.5 mg/kg shows the anticonvulsant effect and at a dose of 30 mg/kg shows proconvulsant effect. However, a different pattern was observed in the mice treated chronically with morphine: they demonstrated tolerance in the tail-flick test; five consecutive days of chronic treatment with a high dose of morphine (30 mg/kg) showed anticonvulsant effect while a low dose of morphine (0.5 mg/kg) showed a proconvulsant effect. The anticonvulsant effect of morphine was inhibited completely by the concomitant administration of NO synthase (NOS) inhibitors including nonspecific NOS inhibitor (L-NAME, 10 mg/kg), inducible NOS inhibitor (aminoguanidine, 50 mg/kg), and neuronal NOS inhibitor (7-nitroindazole (7-NI), 15 mg/kg) for five consecutive days. Besides, five days injection of NMDA-R antagonist (MK-801, 0.05 mg/kg) significantly inhibited the anticonvulsant effect of morphine on the PTZ-induced clonic seizures. The results revealed that chronic treatment with morphine leads to the development of tolerance in mice, which in turn may cause an anticonvulsant effect in a high dose of morphine via the NMDA-R/NO pathway.
N-甲基-D-天冬氨酸受体(NMDA-R)/一氧化氮(NO)通路参与了阿片类药物镇痛作用的增强以及阿片类药物耐受和依赖强度的降低。在本研究中,我们研究了 NMDA-R/NO 通路在慢性吗啡处理的小鼠中的参与作用,包括吗啡镇痛作用的耐受发展和戊四氮(PTZ)诱导的惊厥阈。慢性吗啡(30mg/kg)治疗表现出对吗啡诱导的耐受小鼠的癫痫发作抗性增加。当与一氧化氮合酶(NOS)抑制剂和 NMDA-R 拮抗剂一起使用时,吗啡的耐受发展被撤回,这表明对吗啡(30mg/kg)的抗惊厥作用的耐受发展是通过 NMDA-R/NO 通路介导的。在急性吗啡治疗中,观察到吗啡的剂量依赖性双相惊厥调节;急性治疗 0.5mg/kg 剂量表现出抗惊厥作用,而 30mg/kg 剂量表现出促惊厥作用。然而,在慢性吗啡处理的小鼠中观察到不同的模式:它们在尾部闪烁测试中表现出耐受;连续五天用高剂量吗啡(30mg/kg)慢性治疗表现出抗惊厥作用,而低剂量吗啡(0.5mg/kg)表现出促惊厥作用。NO 合酶(NOS)抑制剂的同时给药完全抑制了吗啡的抗惊厥作用,包括非特异性 NOS 抑制剂(L-NAME,10mg/kg)、诱导型 NOS 抑制剂(氨基胍,50mg/kg)和神经元 NOS 抑制剂(7-硝基吲唑(7-NI),15mg/kg)连续五天。此外,NMDA-R 拮抗剂(MK-801,0.05mg/kg)的五天注射显著抑制了吗啡对 PTZ 诱导的阵挛性惊厥的抗惊厥作用。结果表明,慢性吗啡处理导致小鼠产生耐受,这反过来可能通过 NMDA-R/NO 通路导致高剂量吗啡产生抗惊厥作用。